摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Ethyl 4-(6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl)piperidine-1-carboxylate | 433692-66-1

中文名称
——
中文别名
——
英文名称
Ethyl 4-(6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl)piperidine-1-carboxylate
英文别名
——
Ethyl 4-(6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl)piperidine-1-carboxylate化学式
CAS
433692-66-1
化学式
C22H21Br2ClN2O2
mdl
——
分子量
540.682
InChiKey
BCGPEBPVPBSMQY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    29
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    42.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Ethyl 4-(6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl)piperidine-1-carboxylateN-甲基吗啉盐酸乙胺嗪碳酸氢钠1-羟基苯并三唑三氟乙酸 作用下, 生成 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
    参考文献:
    名称:
    Bridgehead modification of trihalocycloheptabenzopyridine lead to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability
    摘要:
    Modification of the ethano bridge of the core structure of the antitumor agent, SARASAR(R) (SCH66336) with concomitant introduction of a sulfonamide moiety off the distal piperidine afforded inhibitor 9-(S-), a compound with greatly improved PK profile. Other compounds with enhanced FPTase inhibitory activity were obtained as exemplified by amide 10-(S-) and urea 11-(S-): these compounds demonstrated activity in picomolar range. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.09.020
  • 作为产物:
    参考文献:
    名称:
    Bridgehead modification of trihalocycloheptabenzopyridine lead to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability
    摘要:
    Modification of the ethano bridge of the core structure of the antitumor agent, SARASAR(R) (SCH66336) with concomitant introduction of a sulfonamide moiety off the distal piperidine afforded inhibitor 9-(S-), a compound with greatly improved PK profile. Other compounds with enhanced FPTase inhibitory activity were obtained as exemplified by amide 10-(S-) and urea 11-(S-): these compounds demonstrated activity in picomolar range. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.09.020
点击查看最新优质反应信息

文献信息

  • Bridgehead modification of trihalocycloheptabenzopyridine lead to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability
    作者:F. George Njoroge、Bancha Vibulbhan、Xiongwei Shi、Corey Strickland、Paul Kirschmeier、Robert Bishop、Amin Nomeir、Viyyoor Girijavallabhan
    DOI:10.1016/j.bmcl.2004.09.020
    日期:2004.12
    Modification of the ethano bridge of the core structure of the antitumor agent, SARASAR(R) (SCH66336) with concomitant introduction of a sulfonamide moiety off the distal piperidine afforded inhibitor 9-(S-), a compound with greatly improved PK profile. Other compounds with enhanced FPTase inhibitory activity were obtained as exemplified by amide 10-(S-) and urea 11-(S-): these compounds demonstrated activity in picomolar range. (C) 2004 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

马来酸阿扎他啶 脱羧氯雷他定杂质B 盐酸氯雷他定 盐酸氯雷他定 洛那法尼 氯雷他定脱氯杂质 氯雷他定环氧化物 氯雷他定杂质I 氯雷他定杂质F 氯雷他定杂质C 氯雷他定杂质50 氯雷他定杂质29 氯雷他定杂质26 氯雷他定杂质17 氯雷他定杂质14 氯雷他定杂质1 氯雷他定杂质 氯雷他定8-溴代杂质 氯雷他定 托吡林 富马酸卢帕他定 地氯雷他定杂质14 地氯雷他定杂质1 地氯雷他定异构体 地氯雷他定-D4 地氯雷他定 去氯雷他定-N-羟基哌啶 卢帕他定杂质C 卢帕他定杂质B 卢帕他定杂质2 卢帕他定杂质 卢帕他定 乙基4-[8-氯-4-(羟基甲基)-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基]-1-哌啶羧酸酯 乙基4-(8-氯-3-羟基-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基)-1-哌啶羧酸酯 乙基4-(8-氯-3-甲氧基-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基)-1-哌啶羧酸酯 乙基4-(8-氯-1-氧代-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基)-1-哌啶羧酸酯 [4-(8-氯-5,6-二氢-11H-苯并[5,6]环庚[1,2-b]吡啶基-11亚烷基)-1-哌啶基](1H-1,2,4-三唑-1-基)甲酮 N-甲酰基地氯雷他定 N-亚硝基地氯雷他定 N-乙酰基地氯雷他定 D3-3-氧代丁酸甲酯 8-脱氯-9-氯氯雷他定 8-脱氯-9-氯地氯雷他定 8-脱氯-9-氯-N-甲基地氯雷他定 8-氯-6,11-二氢-11-(4-哌啶基亚基)-5H-苯并[5,6]环庚三烯并[1,2-B]吡啶-2,3,4,5,5-D5 8-氯-6,11-二氢-11-(1-甲基-4-哌啶基)-5H-苯并[5,6]环庚烷[1,2-b]吡啶-11-醇 8-氯-6,11-二氢-11-(1-甲基-4-哌啶叉)-5H-苯并[5,6]环庚烷[1,2-b]吡啶 8-氯-5,6-二氢-11H-苯并[5,6]环庚烷并[1,2-b]吡啶-11-酮 8-氯-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮 1-氧化物 8-氯-3-甲氧基-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮